Literature DB >> 33409735

Diaphragmatic Peritonectomy and Full-Thickness Resection in CRS/HIPEC May Allow Higher Completeness of Cytoreduction Rates with a Low Rate of Respiratory Complications.

Andrea Craus-Miguel1,2, Juan José Segura-Sampedro3,4,5, Xavier González-Argenté1,2,6, Rafael Morales-Soriano1,2.   

Abstract

BACKGROUND: Cytoreductive surgery (CRS) provides a survival benefit when achieved without residual disease. As diaphragm is frequently affected in peritoneal malignancies, complete cytoreduction often requires surgical techniques over the diaphragm. The purpose of the study was to assess diaphragmatic resection impact on cytoreduction completeness, morbidity and mortality compared to less aggressive diaphragmatic peritonectomy in CRS and hyperthermic intraperitoneal chemotherapy (HIPEC) settings.
MATERIALS AND METHODS: Patients with peritoneal carcinomatosis and supramesocolic disease undergoing CRS/HIPEC from 2011 to 2019 were included in a prospectively collected database. We compared patients who underwent full-thickness diaphragmatic resection (DR) and diaphragmatic peritonectomy (DP). Epidemiological and clinical data, morbidity, and mortality within 90 days of surgery were documented.
RESULTS: 232 patients were initially selected. Inclusion criteria were met by 88 procedures. DR was performed on 32 patients and DP on 56. Number of resected organs was 5.21 in the DR cohort vs. 3.57 in the DP cohort (p<0.0001). Rate of Peritoneal Cancer Index (PCI) score >14 was higher in the DR group (75%) than in the DP group (50.9%) (p=0.027). Tumor invasion of diaphragmatic muscle after DR was confirmed in 89.3% patients. Postoperative pleural effusion was observed in 28 patients (50%) in the DP group and in 17 (53.1%) in the DR group.
CONCLUSIONS: CRS/HIPEC requires specific surgical techniques over the diaphragm to achieve complete cytoreduction. As diaphragmatic muscle invasion is frequent, full-thickness resection may allow a cytoreduction completeness increase without an increased morbidity. Pleural drains are not systematically required as these procedures show low incidence of major respiratory complications.

Entities:  

Year:  2021        PMID: 33409735     DOI: 10.1245/s10434-020-09505-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Goal-directed therapy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a prospective observational study.

Authors:  N Esteve-Pérez; A Ferrer-Robles; G Gómez-Romero; D Fabián-Gonzalez; M Verd-Rodriguez; L C Mora-Fernandez; J J Segura-Sampedro; S Tejada-Gavela; R Morales-Soriano
Journal:  Clin Transl Oncol       Date:  2018-09-14       Impact factor: 3.405

2.  In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Authors:  Lele Shashikant; P Kesterson Joshua
Journal:  J Obstet Gynaecol India       Date:  2009 May-Jun

3.  A collaborative surgical approach to upper and lower abdominal cytoreductive surgery in ovarian cancer.

Authors:  Oliver S Eng; Mustafa Raoof; Andrew M Blakely; Xian Yu; Stephen J Lee; Ernest S Han; Mark T Wakabayashi; Bertram Yuh; Byrne Lee; Thanh H Dellinger
Journal:  J Surg Oncol       Date:  2018-06-07       Impact factor: 3.454

4.  Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer.

Authors:  David F Silver
Journal:  Gynecol Oncol       Date:  2004-11       Impact factor: 5.482

5.  Operative findings, early complications, and long-term survival in 456 patients with pseudomyxoma peritonei syndrome of appendiceal origin.

Authors:  Haney Youssef; Christopher Newman; Kandiah Chandrakumaran; Faheez Mohamed; Tom D Cecil; Brendan J Moran
Journal:  Dis Colon Rectum       Date:  2011-03       Impact factor: 4.585

6.  8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.

Authors:  Vic J Verwaal; Sjoerd Bruin; Henk Boot; Gooike van Slooten; Harm van Tinteren
Journal:  Ann Surg Oncol       Date:  2008-06-03       Impact factor: 5.344

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

Authors:  Tristan D Yan; Marcello Deraco; Dario Baratti; Shigeki Kusamura; Dominique Elias; Olivier Glehen; François N Gilly; Edward A Levine; Perry Shen; Faheez Mohamed; Brendan J Moran; David L Morris; Terence C Chua; Pompiliu Piso; Paul H Sugarbaker
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

8.  European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery.

Authors:  Denis Querleu; François Planchamp; Luis Chiva; Christina Fotopoulou; Desmond Barton; David Cibula; Giovanni Aletti; Silvestro Carinelli; Carien Creutzberg; Ben Davidson; Philip Harter; Lene Lundvall; Christian Marth; Philippe Morice; Arash Rafii; Isabelle Ray-Coquard; Andrea Rockall; Christiana Sessa; Ate van der Zee; Ignace Vergote; Andreas duBois
Journal:  Int J Gynecol Cancer       Date:  2017-09       Impact factor: 3.437

9.  Experiences with the standardized classification of surgical complications (Clavien-Dindo) in general surgery patients.

Authors:  M Bolliger; J-A Kroehnert; F Molineus; D Kandioler; M Schindl; P Riss
Journal:  Eur Surg       Date:  2018-07-24       Impact factor: 0.953

10.  Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.

Authors:  Willemien J van Driel; Simone N Koole; Karolina Sikorska; Jules H Schagen van Leeuwen; Henk W R Schreuder; Ralph H M Hermans; Ignace H J T de Hingh; Jacobus van der Velden; Henriëtte J Arts; Leon F A G Massuger; Arend G J Aalbers; Victor J Verwaal; Jacobien M Kieffer; Koen K Van de Vijver; Harm van Tinteren; Neil K Aaronson; Gabe S Sonke
Journal:  N Engl J Med       Date:  2018-01-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.